FAP and metastatic prostate carcinoma: External validation confirmed positive correlations for FAP and angiogenesis receptors FLT1, KDR, and KIT as well as HIF1A and ETS1 in hepatocellular carcinoma but also in metastatic prostate cancer (Dream Team cohort) (Figure 5c).